CURE:AU:AU-ETFS S&P Biotech ETF (AUD)

ETF | Others |

Last Closing

USD 48.46

Change

0.00 (0.00)%

Market Cap

USD 0.04B

Volume

1.57K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.68 (+0.66%)

USD 16.05B
VAS:AU Vanguard Australian Shares

+0.68 (+0.66%)

USD 16.05B
VGS:AU Vanguard MSCI International Sh..

-1.17 (-0.92%)

USD 8.59B
VGS:AU Vanguard MSCI International Sh..

-1.17 (-0.92%)

USD 8.59B
IVV:AU iShares Core S&P 500 AUD

-0.58 (-1.04%)

USD 8.26B
IVV:AU iShares Core S&P 500 AUD

-0.58 (-1.04%)

USD 8.26B
QUAL:AU VanEck Vectors MSCI World ex A..

-0.53 (-0.97%)

USD 6.31B
QUAL:AU VanEck Vectors MSCI World ex A..

-0.53 (-0.97%)

USD 6.31B
IOZ:AU Ishares Core S&P/Asx 200

+0.14 (+0.42%)

USD 6.10B
IOZ:AU Ishares Core S&P/Asx 200

+0.14 (+0.42%)

USD 6.10B

ETFs Containing CURE:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.85% 42% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.85% 31% F 58% F
Trailing 12 Months  
Capital Gain 24.42% 84% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.42% 80% B- 75% C
Trailing 5 Years  
Capital Gain 3.11% 37% F 59% D-
Dividend Return 13.37% 62% D 44% F
Total Return 16.48% 37% F 59% D-
Average Annual (5 Year Horizon)  
Capital Gain -2.67% N/A N/A 36% F
Dividend Return -0.28% N/A N/A 37% F
Total Return 2.39% N/A N/A 46% F
Risk Return Profile  
Volatility (Standard Deviation) 21.75% N/A N/A 72% C
Risk Adjusted Return -1.30% N/A N/A 37% F
Market Capitalization 0.04B 10% F 46% F

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.